BRIEF-Ocuphire Pharma Publishes Full Phase 3 Results Of Phentolamine Ophthalmic Solution 0.75%

Reuters09-30

Sept 30 (Reuters) - Ocuphire Pharma Inc :

* OCUPHIRE PHARMA ANNOUNCES PUBLICATION OF FULL PHASE 3 RESULTS OF PHENTOLAMINE OPHTHALMIC SOLUTION 0.75% FOR PHARMACOLOGICALLY-INDUCED MYDRIASIS IN OPHTHALMOLOGY

* OCUPHIRE PHARMA INC: PHENTOLAMINE OPHTHALMIC SOLUTION 0.75% EXHIBITED A FAVORABLE SAFETY PROFILE

* OCUPHIRE PHARMA INC: VEGA-3 PHASE 3 CLINICAL TRIAL TOP-LINE DATA ARE EXPECTED IN FIRST HALF OF 2025

* OCUPHIRE PHARMA INC: LYNX-2 PHASE 3 TRIAL TOP-LINE DATA ARE EXPECTED IN Q1 OF 2025.

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2471880470?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-30 20:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2471880470","market":"us","top_or_hot":-1,"title":"BRIEF-Ocuphire Pharma Publishes Full Phase 3 Results Of Phentolamine Ophthalmic Solution 0.75%","media":"Reuters","content":"<html><body><p>Sept 30 (Reuters) - Ocuphire Pharma Inc   :</p><p>   * OCUPHIRE PHARMA ANNOUNCES PUBLICATION OF FULL PHASE 3 RESULTS OF PHENTOLAMINE OPHTHALMIC SOLUTION 0.75% FOR PHARMACOLOGICALLY-INDUCED MYDRIASIS IN OPHTHALMOLOGY</p><p>   * OCUPHIRE PHARMA INC: PHENTOLAMINE OPHTHALMIC SOLUTION 0.75% EXHIBITED A FAVORABLE SAFETY PROFILE</p><p>   * OCUPHIRE PHARMA INC:  VEGA-3 PHASE 3 CLINICAL TRIAL TOP-LINE DATA ARE EXPECTED IN FIRST HALF OF 2025</p><p>   * OCUPHIRE PHARMA INC:  LYNX-2 PHASE 3 TRIAL TOP-LINE DATA ARE EXPECTED IN Q1 OF 2025.</p><p>Source text for Eikon:   Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Ocuphire Pharma Publishes Full Phase 3 Results Of Phentolamine Ophthalmic Solution 0.75%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Ocuphire Pharma Publishes Full Phase 3 Results Of Phentolamine Ophthalmic Solution 0.75%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-30 20:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sept 30 (Reuters) - Ocuphire Pharma Inc   :   * OCUPHIRE PHARMA ANNOUNCES PUBLICATION OF FULL PHASE 3 RESULTS OF PHENTOLAMINE OPHTHALMIC SOLUTION 0.75% FOR PHARMACOLOGICALLY-INDUCED MYDRIASIS IN ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2471880470","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2471880470","pubTimestamp":1727699255,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Sept 30  - Ocuphire Pharma Inc   :   * OCUPHIRE PHARMA ANNOUNCES PUBLICATION OF FULL PHASE 3 RESULTS OF PHENTOLAMINE OPHTHALMIC SOLUTION 0.75% FOR PHARMACOLOGICALLY-INDUCED MYDRIASIS IN OPHTHALMOLOGY   * OCUPHIRE PHARMA INC: PHENTOLAMINE OPHTHALMIC SOLUTION 0.75% EXHIBITED A FAVORABLE SAFETY PROFILE   * OCUPHIRE PHARMA INC:  VEGA-3 PHASE 3 CLINICAL TRIAL TOP-LINE DATA ARE EXPECTED IN FIRST HALF OF 2025   * OCUPHIRE PHARMA INC:  LYNX-2 PHASE 3 TRIAL TOP-LINE DATA ARE EXPECTED IN Q1 OF 2025.Source text for Eikon:   Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药"},"translate_title":"简介-Ocuphire Pharma公布0.75%酚妥拉明滴眼液的完整3期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCUP":0.9},"content_text":"Sept 30 (Reuters) - Ocuphire Pharma Inc   :   * OCUPHIRE PHARMA ANNOUNCES PUBLICATION OF FULL PHASE 3 RESULTS OF PHENTOLAMINE OPHTHALMIC SOLUTION 0.75% FOR PHARMACOLOGICALLY-INDUCED MYDRIASIS IN OPHTHALMOLOGY   * OCUPHIRE PHARMA INC: PHENTOLAMINE OPHTHALMIC SOLUTION 0.75% EXHIBITED A FAVORABLE SAFETY PROFILE   * OCUPHIRE PHARMA INC:  VEGA-3 PHASE 3 CLINICAL TRIAL TOP-LINE DATA ARE EXPECTED IN FIRST HALF OF 2025   * OCUPHIRE PHARMA INC:  LYNX-2 PHASE 3 TRIAL TOP-LINE DATA ARE EXPECTED IN Q1 OF 2025.Source text for Eikon:   Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2471880470"}